Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11033-020-06060-8 http://scihub22266oqcxt.onion/10.1007/s11033-020-06060-8 33313973!7733534!33313973     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Biol+Rep 2021 ; 48 (1): 983-987 Nephropedia Template TP {{tp|p=33313973|t=2021. BRCA testing delay during the COVID-19 pandemic: How to act?|pdf=|usr=}}{{33313973}} gab.com Text BRCA testing delay during the COVID-19 pandemic: How to act JO: Mol Biol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33313973 #FOAvip Recently, our lab, part of a referral center in Italy, reported its experience regarding the execution of germline BRCA1/2 (gBRCA) testing during the first months of the coronavirus disease-2019 (COVID-19) pandemic, which highlights a substantial reduction (about 60%) compared with the first 2 months of the current year. This evidence appeared to be a lockdown effect due to extraordinary restriction measures to slow down the spread of SARS-CoV-2. In this study, we aimed to evaluate the overall effects of the ongoing pandemic on gBRCA testing in our institution and to understand how COVID-19 has influenced testing after the complete lockdown (March 8-May 5, 2020). Additionally, we compared this year's trend with trends of the last 3 years to better monitor gBRCA testing progress. This detailed analysis highlights two important findings: (1) gBRCA testing did not increase significantly after the lockdown period (May-October 2020) compared with the lockdown period (March-April 2020), emphasizing that even after the lockdown period testing remained low. (2) Comparing the total tests per year (January-October 2017, 2018, 2019, with 2020), the impact of COVID-19 on gBRCA testing is apparent, with similarities of trends registered in 2017. These evidences reveal a gBRCA testing delay for cancer patients and healthy patients at this moment, and the new era of gBRCA testing in the management of ovarian, breast, pancreas and prostate cancer patients has been seriously questioned due to the COVID-19 pandemic. As consequence, we underline that measures to guarantee oncogenetic testing (e.g., gBRCA testing) along with new diagnostic/clinic strategies are mandatory. For these reasons, several proposals are presented in this study. Twit Text FOAVip BRCA testing delay during the COVID-19 pandemic: How to act ????Mol Biol Rep http://www.kidney.de/pget.php?&tw=1&pmid=33313973 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33313973 #FOAvip English Wikipedia <ref>{{Cite pmid|33313973}}</ref> BRCA testing delay during the COVID-19 pandemic: How to act? #MMPMID33313973 Minucci A; Scambia G; De Bonis M; De Paolis E; Santonocito C; Fagotti A; Capoluongo E; Concolino P; Urbani A Mol Biol Rep 2021[Jan]; 48 (1): 983-987 PMID33313973show ga Recently, our lab, part of a referral center in Italy, reported its experience regarding the execution of germline BRCA1/2 (gBRCA) testing during the first months of the coronavirus disease-2019 (COVID-19) pandemic, which highlights a substantial reduction (about 60%) compared with the first 2 months of the current year. This evidence appeared to be a lockdown effect due to extraordinary restriction measures to slow down the spread of SARS-CoV-2. In this study, we aimed to evaluate the overall effects of the ongoing pandemic on gBRCA testing in our institution and to understand how COVID-19 has influenced testing after the complete lockdown (March 8-May 5, 2020). Additionally, we compared this year's trend with trends of the last 3 years to better monitor gBRCA testing progress. This detailed analysis highlights two important findings: (1) gBRCA testing did not increase significantly after the lockdown period (May-October 2020) compared with the lockdown period (March-April 2020), emphasizing that even after the lockdown period testing remained low. (2) Comparing the total tests per year (January-October 2017, 2018, 2019, with 2020), the impact of COVID-19 on gBRCA testing is apparent, with similarities of trends registered in 2017. These evidences reveal a gBRCA testing delay for cancer patients and healthy patients at this moment, and the new era of gBRCA testing in the management of ovarian, breast, pancreas and prostate cancer patients has been seriously questioned due to the COVID-19 pandemic. As consequence, we underline that measures to guarantee oncogenetic testing (e.g., gBRCA testing) along with new diagnostic/clinic strategies are mandatory. For these reasons, several proposals are presented in this study. |*Pandemics[MESH] |BRCA1 Protein/*blood[MESH] |Biomarkers, Tumor/blood[MESH] |Breast Neoplasms/*diagnosis[MESH] |COVID-19/*epidemiology/psychology[MESH] |Delayed Diagnosis/ethics[MESH] |Early Detection of Cancer/statistics & numerical data[MESH] |Female[MESH] |Health Policy[MESH] |Humans[MESH] |Italy/epidemiology[MESH] |Male[MESH] |Ovarian Neoplasms/*diagnosis[MESH] |Pancreatic Neoplasms/*diagnosis[MESH] |Physical Distancing[MESH] |Prostatic Neoplasms/*diagnosis[MESH] |Quarantine/psychology[MESH]BRCA testing delay during the COVID-19 pandemic: How to act?(epmc).pdf DeepDyve Pubget Overpricing